Broad-Spectrum Antagonists For Editors (B-SAFE)
Closed Posted
- Opportunity number
- HR001124S0032
- Agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement, Procurement Contract
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Other
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Defense Advanced Research Projects Agency (DARPA) is seeking innovative proposals for the Broad-Spectrum Antagonists For Editors (B-SAFE) program. This program aims to identify and optimize novel molecules that can inhibit CRISPR-Cas gene editing processes, with a focus on enhancing the activity, utility, and breadth of coverage of these inhibitors. DARPA is interested in transformative approaches that go beyond incremental improvements to the existing state-of-the-art. Proposals will be evaluated based on technical merit, relevance to DARPA's mission, and cost realism. Abstract submissions are due by July 15, 2024, and full proposals are due by August 12, 2024.
DARPA anticipates making multiple awards ranging from $5-10 million over 2-3 years, potentially through cooperative agreements, procurement contracts, or other transaction agreements. The program seeks to scale up top-performing inhibitor molecules for testing and evaluation by Department of Defense stakeholders, with the goal of promoting the safe and controlled use of gene editing technologies.
Synopsis
2 versions
Update #2 · Latest ·
The purpose of Amendment 1 to HR001124S032, the Broad-Spectrum Antagonists For Editors (B-SAFE) Broad Agency Announcement, is to clarify the content of Tables 1 and 4 and the proposal abstract submission requirements, and add a Risk Register attachment. - The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to identify and optimize novel molecules that exhibit inhibitory effects on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated proteins (CRISPR-Cas) gene editing processes. The Broad-Spectrum Antagonists for Editors (B-SAFE) program is explicitly seeking transformative approaches enabling the discovery or design of novel inhibitors of gene editing technologies with enhanced activity, utility, and breadth of coverage. Novel inhibitor activity will be assessed in vitro over the course of the program and a subset of top performing molecules will be selected for scale-up at quantities sufficient for testing and evaluation by Department of Defense (DoD) stakeholders. In concert, DARPA is interested in exploring methods to rapidly discover inhibitor molecules for novel gene editing technologies beyond CRISPR-Cas systems to keep pace with the rapidly advancing field and promote the safe, controlled use of these technologies. Research that generates incremental improvements to the existing state-of-the-art are specifically excluded.
Update #1 ·
The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals to identify and optimize novel molecules that exhibit inhibitory effects on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated proteins (CRISPR-Cas) gene editing processes. The Broad-Spectrum Antagonists for Editors (B-SAFE) program is explicitly seeking transformative approaches enabling the discovery or design of novel inhibitors of gene editing technologies with enhanced activity, utility, and breadth of coverage. Novel inhibitor activity will be assessed in vitro over the course of the program and a subset of top performing molecules will be selected for scale-up at quantities sufficient for testing and evaluation by Department of Defense (DoD) stakeholders. In concert, DARPA is interested in exploring methods to rapidly discover inhibitor molecules for novel gene editing technologies beyond CRISPR-Cas systems to keep pace with the rapidly advancing field and promote the safe, controlled use of these technologies. Research that generates incremental improvements to the existing state-of-the-art are specifically excluded.
Files
| File | Type | Posted |
|---|---|---|
| B-SAFE_QA_v2.docx | DOCX document | |
| HR001124S0032_Attachment_G_Risk_Register.xlsx | XLSX spreadsheet | |
| HR001124S0032_Attachment_B_Abstract_Template_V2.docx | DOCX document | |
| HR001124S0032-Amendment-01.pdf | ||
| Attachment_F_DARPAStandardCostProposalSpreadSheet_TwoTAs.xlsx | XLSX spreadsheet | |
| Attachment_E_Proposal_Instructions_and_Volume_II_Template__Cost_revised20240614_1350.docx | DOCX document | |
| HR001124S0032_Attachment_C_Proposal_Summary_Slide_Template.pptx | PPTX presentation | |
| Attachment_D_Proposal_Instructions_and_Volume_I_Template__Technical_and_Management_revised20240614_1350.docx | DOCX document | |
| HR001124S0032_Attachment_B_Abstract_Template.docx | DOCX document | |
| HR001124S0032_Attachment_A_Abstract_Summary_Slide_Template.pptx | PPTX presentation | |
| HR001124S0032.pdf |
Show all 11
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity